Alkermes Set to Take Part in Important Neuropsychiatry Conference
Alkermes plc (Nasdaq: ALKS) has announced its involvement in a major neuroscience event. The TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference this year will serve as a venue to discuss fresh perspectives on mental health treatments.
What Attendees Can Anticipate from the Conference
At the conference, Alkermes' management team will engage in a fireside chat presentation. This event will take place in September, where they’ll discuss advancements in neuropsychiatry and Alkermes’ contributions to enhancing treatment options.
Availability of the Live Webcast
The live presentation is open to the public, accessible through the Investors tab on Alkermes’ official website. This offers a chance for anyone interested to listen in on the valuable insights shared. Additionally, for those who can’t attend live, the webcast will be archived so they can catch up on the discussions later.
About Alkermes plc: A Key Player in Neuroscience
Alkermes plc distinguishes itself as a global biopharmaceutical company focused on creating innovative therapeutic solutions for neurological disorders. Their product lineup includes proprietary treatments for alcohol and opioid dependence, schizophrenia, and bipolar I disorder. Alongside these, Alkermes is also developing a robust pipeline of clinical and preclinical candidates aimed at addressing specific neurological conditions such as narcolepsy.
Worldwide Presence and Dedication to Innovation
With its headquarters in Ireland, Alkermes boasts a research and development center and corporate office in Massachusetts, as well as a cutting-edge manufacturing facility in Ohio. This arrangement underscores their commitment to innovation, keeping them at the forefront of advancements in neuroscience.
Engaging with Alkermes
Alkermes' dedication to tackling serious neurological issues makes it an essential player in the biopharmaceutical industry. Stakeholders and those interested can connect with the company to learn more about its vision and contributions to neuroscience via their website.
Contact Details
For any inquiries, Alkermes has an Investor Relations team led by Jamie Constantine. Potential investors and other interested parties can reach out directly by calling +1 781 873 2402.
Frequently Asked Questions
What is the TD Cowen 4th Annual Neuropsychiatry Conference?
This conference highlights innovative mechanisms in neuropsychiatry, emphasizing advanced treatment options and research findings in the field.
When is Alkermes taking part in the conference?
Alkermes will participate in the conference in September; specific details about their presentation time will be made available publicly.
How can I view the conference webcast?
The live webcast will be available through Alkermes' official website, located in the Investors tab, and will be offered on-demand for 14 days following the event.
What kinds of treatments does Alkermes offer?
Alkermes develops therapies for conditions such as alcohol and opioid dependence, schizophrenia, bipolar I disorder, and other neurological disorders.
Who should I contact for more information about Alkermes?
If you need further details, you can reach out to Jamie Constantine from the Investor Relations department at Alkermes.